Opinion|Videos|November 15, 2024
Combination Therapies in BRAF-Positive NSCLC
Panelists discuss their insights on current and emerging combination strategies in the treatment of BRAF-positive NSCLC, focusing on the integration of targeted therapies, immunotherapies, or both.
Advertisement
- Dr Gadgeel: What are your thoughts on the current and emerging combination strategies in BRAF- positive NSCLC treatment, particularly those involving targeted therapies, immunotherapies, or both? (
Planchard D, et al. NPJ Precis Oncol. 2024 )
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5
































